MedTrace Logo

Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy

NCT03270007 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2020-10-28

No results posted yet for this study

Summary

This is a phase IV, single-center, prospective, open-label, randomized,controlled study

Conditions

  • Primary Breast Cancer

Interventions

DRUG

Vinorelbine

different from primary chemotherapy(containing anthracycline or paclitaxel)

Sponsors & Collaborators

  • Tao OUYANG

    lead OTHER

Principal Investigators

  • Xing Wang, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
66 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-10
Primary Completion
2024-06-30
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03270007 on ClinicalTrials.gov